Skip to main content
Clinical Trials/NCT06127550
NCT06127550
Suspended
N/A

Effect of Non-invasive Vagus Nerve Stimulation on Letter Learning in Dyslexia

University of Florida1 site in 1 country100 target enrollmentAugust 1, 2026
ConditionsDyslexia

Overview

Phase
N/A
Intervention
Not specified
Conditions
Dyslexia
Sponsor
University of Florida
Enrollment
100
Locations
1
Primary Endpoint
Adverse events
Status
Suspended
Last Updated
4 months ago

Overview

Brief Summary

This is a pilot study to establish feasibility of transcutaneous auricular vagus nerve stimulation (taVNS) for improving letter-learning in adolescents with dyslexia. The main goals of the study are to 1) evaluate whether children in this age range will tolerate low level stimulation over the course of multiple sessions, 2) determine whether low level taVNS improves novel letter learning in dyslexia, and 3) evaluate the effect of low level taVNS on the brain's response to letters. Participants will complete fMRI before training, immediately after training, and a few weeks after training ends. Training will consist of six 30-minute lessons during which participants will learn novel letter-sound relationships while receiving either active or sham taVNS. Researchers will compare stimulation conditions to determine effect of this device on learning and neural plasticity.

Registry
clinicaltrials.gov
Start Date
August 1, 2026
End Date
September 1, 2029
Last Updated
4 months ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Normal non-verbal IQ
  • Reading scores above 90 on four single word reading measures (typical reader) OR reading scores below 90 on two or more single word reading measures (dyslexia) with or without ADHD

Exclusion Criteria

  • Neurological diagnoses (e.g., autism, epilepsy, etc.)
  • Medications other than those prescribed for ADHD
  • Nonverbal IQ below 80

Outcomes

Primary Outcomes

Adverse events

Time Frame: 4 weeks

Frequency and severity of adverse events will be monitored and evaluated for severity and impact on attrition.

Compliance

Time Frame: 4 weeks

Percentage of the population that remains engaged in the study and completes all stimulation sessions.

Secondary Outcomes

  • Letter ID(6 weeks)
  • Decoding(6 weeks)
  • Automaticity(6 weeks)

Study Sites (1)

Loading locations...

Similar Trials